Targeting immune checkpoints in malignant glioma.
Targeting immune checkpoints in malignant glioma.
复制标题
针对恶性胶质瘤的免疫检查点
DOI：
10.18632/oncotarget.12702
复制
发表时间：
2017-01-24
期刊：
影响因子：
--
通讯作者：
Chen J
中科院分区：
文献类型：
--
作者：
Zhang X;Zhu S;Li T;Liu YJ;Chen W;Chen J
恶性胶质瘤是中枢神经系统（CNS）中最常见、侵袭性极强的癌症。癌症免疫疗法是一种增强人体抗癌免疫反应而非直接针对肿瘤细胞的策略，最近在治疗多种人类实体瘤方面取得了巨大成功。虽然中枢神经系统曾被认为是免疫特权区，没有正常的免疫功能，但由于神经生物学和神经免疫学的最新进展以及恶性胶质瘤的高度免疫抑制状态，中枢神经系统现在被认为是癌症免疫疗法的一个有希望的靶点。在这篇综述中，我们将重点关注免疫检查点抑制剂，特别是拮抗程序性细胞死亡蛋白-1（PD-1）、细胞毒性T淋巴细胞相关抗原-4（CTLA-4）和吲哚胺2,3-二氧化酶（IDO）的单克隆抗体。我们将讨论这些免疫检查点分子工作机制的进展、它们在恶性胶质瘤中的地位，以及目前针对这些分子治疗恶性胶质瘤的临床前和临床试验。
Malignant glioma is the most common and a highly aggressive cancer in the central nervous system (CNS). Cancer immunotherapy, strategies to boost the bodys anti-cancer immune responses instead of directly targeting tumor cells, recently achieved great success in treating several human solid tumors. Although once considered immune privileged and devoid of normal immunological functions, CNS is now considered a promising target for cancer immunotherapy, featuring the recent progresses in neurobiology and neuroimmunology and a highly immunosuppressive state in malignant glioma. In this review, we focus on immune checkpoint inhibitors, specifically, antagonizing monoclonal antibodies for programmed cell death protein-1 (PD-1), cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), and indoleamine 2,3-dioxygenase (IDO). We discuss advances in the working mechanisms of these immune checkpoint molecules, their status in malignant glioma, and current preclinical and clinical trials targeting these molecules in malignant glioma.